Hematologic Neoplasms
Conditions
Keywords
Hematopoietic Stem Cell Transplantation
Brief summary
The administration of high-dose chemotherapy followed by the infusion of blood or bone marrow stem cells (stem cell transplantation) from a matched donor has become standard treatment for patients with high-risk or relapsed hematological cancers. Currently, donors are found for approximately 80% of people who require such treatment, although the chance of finding a donor is much lower in some ethnic communities. In the current study the investigators will offer patients requiring transplantation, but for whom well matched donors cannot be identified either from within the family or on the donor registry, a transplant from a half-matched (haploidentical) family member. A myeloablative conditioning regimen and un-manipulated peripheral blood stem cells will be used. Post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil will be used to prevent graft versus host disease (GVHD). The primary outcome measure will be 6 month survival free from graft failure, relapse and grade 3-4 acute GVHD. Other outcomes of interest will include the frequency of Cytomegalovirus (CMV) or Epstein-Barr Virus (EBV) requiring treatment, overall survival and progression-free survival.
Interventions
PROCEDURET-Cell replete haplo-transplant
Infusion of haploidentical related donor peripheral blood stem cells following myeloablative conditioning (fludarabine 200 mg/m2, busulfan 12.8 mg/kg and total body irradiation (TBI) 400 centigray -or- fludarabine 200 mg/m2, busulfan 9.6 mg/kg). GVHD prophylaxis will be with cyclophosphamide 50 mg/kg/day x 2 on days 3 & 4, mycophenolate mofetil 1 gm p.o. bid days 5 - 35 and tacrolimus (5-15 ug/ml) days 5 - 100.
Sponsors
The Canadian Blood and Marrow Transplant Group
University of Calgary
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* A hematological malignancy such as acute leukemia or myelodysplastic syndrome requiring hematopoietic stem cell transplantation. * A haploidentical family member willing to donate. * Suitable performance status, organ function (as defined locally) and disease status for transplantation. * Patients with acute leukemia must be in morphological complete remission. Patients with chronic myelogenous leukemia must be in chronic phase and those with lymphoma must have chemosensitive disease (at least partial remission to most recent chemotherapy regimen). * Given written, informed consent to participate in a clinical trial.
Exclusion criteria
* An 8/8 matched sibling donor or matched unrelated donor (based on high-resolution typing as appropriate), available within a time frame acceptable to the treating physician * Patients with an available single allele or single antigen mismatched donor (7/8 or 9/10) or available cord blood donor can be included at the discretion of the treating team, according to local institutional practice. * Prior allogeneic transplant * Any
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Six month survival, free from relapse, graft failure and grade III/IV acute GVHD | Six months |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative incidence of non-relapse mortality at 1 year | One year |
| Graft failure rate (ANC < 0.5 and low donor chimerism) | Six months |
| Overall and Disease Free Survival | One year |
| Incidence of Chronic Extensive Graft Versus Host Disease | One year |
| Patients remaining on immune suppression at 1 year | One year |
| Incidence of CMV and EBV reactivation requiring treatment | One year |
| Incidence of Grade III/IV Acute Graft Versus Host Disease | Six months |
| Relapse Rate | One year |
Countries
Canada
Outcome results
None listed